Our results suggest that the immunosuppressive role and tumorigenesis of tumor-associated macrophages and regulatory B cells in the immune-competent subtype of NSCLCs could prevent promotion from the antitumor immune response and stimulate the expression of immune checkpoints such as PD-L1 and PD1 by inhibiting CD8+ T cell activation. The gene discussed is CD8A; the disease is neoplasm.